Baidu
map

JBC:癌细胞内组蛋白mH2A1.2与HER-2之间相互作用的机制

2012-05-19 Deepblue 生物谷

原癌基因人类表皮生长因子受体2(HER-2)一般在癌细胞内过量表达,但是其机制目前仍不明确。近日,来自夏威夷大学的研究人员Scott K. Kuwada等人表示,癌细胞内非典型组蛋白macroH2A1.2与HER-2的相互作用能够促进原癌基因的表达及细胞增生。 研究发现,在HER-2过表达的癌细胞内,非典型组蛋白macroH2A1能够与HER-2相互作用。人类mH2A1具有两种亚型,mH2A1.

原癌基因人类表皮生长因子受体2(HER-2)一般在癌细胞内过量表达,但是其机制目前仍不明确。近日,来自夏威夷大学的研究人员Scott K. Kuwada等人表示,癌细胞内非典型组蛋白macroH2A1.2与HER-2的相互作用能够促进原癌基因的表达及细胞增生。

研究发现,在HER-2过表达的癌细胞内,非典型组蛋白macroH2A1能够与HER-2相互作用。人类mH2A1具有两种亚型,mH2A1.2与mH2A1.1。在人癌细胞系,他们发现mH2A1.2而不是mH2A1.1,能够与HER-2相互作用。

在致瘤性及HER-2表达显著提高的癌细胞,他们发现mH2A1.2表现出过表达水平。在癌细胞,抑制HER-2激酶活性,削弱了mH2A1的表达,降低了mH2A1.2诱导的原癌基因ERBB2的转录。

在稳定转染mH2A1.2的癌细胞,染色质免疫共沉淀实验显示,mH2A1.2富集在HER-2的启动子,这表明mH2A1.2具有促进HER-2过表达的作用。

进一步研究表明,进化上保守的mH2A1.2的宏结构域(macro domain),对于HER-2与mH2A1.2的相互作用及mH2A1.2诱导的ERBB2的转录十分必要。

有趣的是,mH2A1.2的宏结构域具有mH2A1.1没有的三核苷酸的插入序列,它可能对HER-2与mH2A1.2的相互作用,对mH2A1.2诱导的ERBB2转录及细胞增生是必不可少的。

Scott K. Kuwada表示,本次发现阐明了mH2A1.2与HER-2之间新的相互作用机制,表明了一个独特的机制,即原癌基因能够广泛的引起癌细胞内基因转录失调

doi: 10.1074/jbc.M112.379412
PMC:
PMID:

The atypical histone macroH2A1.2 interacts with HER-2 in cancer cells

Xiufen Li, Jinqui Kuang, Yi Shen, Martin M. Majer, Chad C. Nelson, Krishna Parsawar, Karen A. Heichman and Scott K. Kuwada

Since HER-2 has been demonstrated in the nuclei of cancer cells we hypothesized that it might interact with transcription factors that activate ERBB2 transcription.macroHistone 2A1 (H2AFY; mH2A1) was found to interact with HER-2 in cancer cells that overexpress HER-2. Of the two human mH2A1 isoforms, mH2A1.2, but not mH2A1.1, interacted with HER-2 in human cancer cell lines.Overexpression of mH2A1.2, but not mH2A1.1, in cancer cells significantly increased HER-2 expression and tumorigenicity. Inhibition of HER-2 kinase activity diminished mH2A1 expression and mH2A1.2-induced ERBB2 transcription in cancer cells.Chromatin immunoprecipitation of mH2A1.2 in cancer cells stably transfected with mH2A1.2 showed enrichment of mH2A1.2 at the HER-2 promoter suggesting a role for mH2A1.2 in driving HER-2 overexpression.The evolutionarily conserved macro domain of mH2A1.2 was sufficient for the interaction between HER-2 and mH2A1.2, and, for mH2A1.2-induced ERBB2 transcription.Within the macro domain of mH2A1.2, a trinucleotide insertion (-eis) sequence not found in mH2A1.1 was essential for the interaction between HER-2 and mH2A1.2 as well as mH2A1.2-induced HER-2 expression and cell proliferation.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1909165, encodeId=6cb41909165c7, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Tue Nov 13 12:14:00 CST 2012, time=2012-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036360, encodeId=43842036360b8, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu Jan 31 03:14:00 CST 2013, time=2013-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251882, encodeId=121112518824b, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384642, encodeId=f4831384642df, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471485, encodeId=7f2714e148551, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495789, encodeId=c7a31495e8994, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1909165, encodeId=6cb41909165c7, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Tue Nov 13 12:14:00 CST 2012, time=2012-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036360, encodeId=43842036360b8, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu Jan 31 03:14:00 CST 2013, time=2013-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251882, encodeId=121112518824b, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384642, encodeId=f4831384642df, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471485, encodeId=7f2714e148551, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495789, encodeId=c7a31495e8994, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
    2013-01-31 lily1616
  3. [GetPortalCommentsPageByObjectIdResponse(id=1909165, encodeId=6cb41909165c7, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Tue Nov 13 12:14:00 CST 2012, time=2012-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036360, encodeId=43842036360b8, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu Jan 31 03:14:00 CST 2013, time=2013-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251882, encodeId=121112518824b, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384642, encodeId=f4831384642df, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471485, encodeId=7f2714e148551, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495789, encodeId=c7a31495e8994, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
    2012-05-21 yxch36
  4. [GetPortalCommentsPageByObjectIdResponse(id=1909165, encodeId=6cb41909165c7, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Tue Nov 13 12:14:00 CST 2012, time=2012-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036360, encodeId=43842036360b8, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu Jan 31 03:14:00 CST 2013, time=2013-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251882, encodeId=121112518824b, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384642, encodeId=f4831384642df, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471485, encodeId=7f2714e148551, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495789, encodeId=c7a31495e8994, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
    2012-05-21 xqptu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1909165, encodeId=6cb41909165c7, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Tue Nov 13 12:14:00 CST 2012, time=2012-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036360, encodeId=43842036360b8, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu Jan 31 03:14:00 CST 2013, time=2013-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251882, encodeId=121112518824b, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384642, encodeId=f4831384642df, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471485, encodeId=7f2714e148551, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495789, encodeId=c7a31495e8994, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
    2012-05-21 ylz8405
  6. [GetPortalCommentsPageByObjectIdResponse(id=1909165, encodeId=6cb41909165c7, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Tue Nov 13 12:14:00 CST 2012, time=2012-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036360, encodeId=43842036360b8, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Thu Jan 31 03:14:00 CST 2013, time=2013-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251882, encodeId=121112518824b, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384642, encodeId=f4831384642df, content=<a href='/topic/show?id=5c74e7739f0' target=_blank style='color:#2F92EE;'>#组蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77739, encryptionId=5c74e7739f0, topicName=组蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea13490, createdName=xqptu, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471485, encodeId=7f2714e148551, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495789, encodeId=c7a31495e8994, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Mon May 21 14:14:00 CST 2012, time=2012-05-21, status=1, ipAttribution=)]
    2012-05-21 zhu_jun9840

相关资讯

FDA:来那度胺增加多发性骨髓瘤患者第二原发肿瘤危险

  2012年5月7日,美国食品与药物管理局(FDA)发布通告称,多项临床试验结果显示,与接受安慰剂治疗相比,新诊断的多发性骨髓瘤(MM)患者接受抗肿瘤药物来那度胺治疗可增加第二原发肿瘤发生危险;尤其是增加急性髓细胞白血病(AML)、骨髓增生异常综合征(MDS)和霍奇金淋巴瘤的危险。来那度胺(商品名:Revlimid)药物标签的警告和注意事项部分和患者用药指导添加了这一安全信息。FDA建议,临床医

Cancer Res:CCL2是肿瘤骨转移的关键机制

密歇根州研究人员发现在肿瘤细胞扎根于骨髓之前使用普通化疗药物,实际上会让肿瘤细胞更容易进入骨髓、生长。 该研究为某些癌症转移到骨的机制提供了宝贵的思路,并有可能最终导致新的转移预防药物的出现。 虽然能有效攻击肿瘤细胞,环磷酰胺和许多其他化疗药物一样具有副作用,会抑制骨髓细胞,影响免疫系统。如果我们更好地理解其中机制,我们可以制定更有效的疗法,以防止局部癌症蔓延,从而减少转移到骨。 真正的好消

Cancer Res:胰腺癌早期生物标志物PEAK1

美国加州大学圣地亚哥分校医学院和穆尔斯癌症中心的研究人员发现一种新的生物标志物和胰腺癌的治疗靶标。相关论文发表在5月15日的Cancer Research杂志上。 胰腺癌是引发癌症相关死亡的第四大原因,初诊患者的平均存活时间不到一年,只有3%至5%的患者有5年生存率。因此,迫切需要的生物标志物来识别胰腺癌发病的初期,这一标志物可能也是可行的药物靶标。 加州大学圣迭戈分校病理学和穆尔斯癌症中心博

PNAS:黑色素瘤转移的标记物PHIP蛋白

近日,发表在PNAS杂志上的一项研究揭示了致命性的皮肤癌黑色素瘤中基因表达的升高,可以提高肿瘤的死亡率风险,该基因是潜在的新的治疗靶标。 研究论文呢题目为Pleckstrin Homology Domain-Interacting Protein (PHIP) as a Marker and Mediator of Melanoma Metastasis,该研究由加州太平洋医疗中心研究所(CPM

PNAS:慢性心理压力促进肿瘤发生的机制

流行病学研究已经表明,慢性心理压力能够促进肿瘤发生。然而在体内,慢性心理压力与肿瘤发生之间的联系以及潜在的机制还不明确。 近日,美国新泽西医科和牙科大学的研究人员对此开展了一项研究,该研究对慢性压力能够促进体内肿瘤发生提供了直接证据。相关论文发表在5月1的PNAS上。 研究发现,在已建立的老鼠模型中,慢性束缚显著促进了电离辐射(IR)诱导的肿瘤生成。 肿瘤抑制蛋白p53在肿瘤抑制中起着极其重

乳腺癌患者白细胞来源微泡比例与肿瘤大小有关

  最近,华中科技大学同济医学院附属协和医院干细胞研究与应用中心的研究人员的一项研究显示,乳腺癌患者的白细胞来源微泡(leukocyte-derived microparticles,LMPs)比例与肿瘤大小有关,而CD44+LMPs比例与Her-2水平密切相关,该指标可用来评估乳腺癌的复发转移及预后情况。该研究发表于2012年第3期《肿瘤》。   该研究旨在探讨乳腺癌患者LMPs的特

Baidu
map
Baidu
map
Baidu
map